C. MichaelGibsonMDMS, FACC, FAHA, FSCA
Cardiology • Boston, MACardiac Electrophysiology, Interventional Cardiology
Professor of Medicine, Harvard Medical School. CEO Baim & PERFUSE Non-Profit Research Institutes. Interventional Cardiologist Beth Israel Deaconess Medical Center. FDA Cardiorenal panel member. Founder WikiDoc & Editor In Chief. @CMichaelGibson on twitter.
Dr. Gibson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
930 Commonwealth Avenue
3rd Floor
Boston, MA 02115Phone+1 617-307-5579
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Cardiovascular Disease, 1989 - 1993
Brigham and Women's HospitalResidency, Internal Medicine, 1986 - 1989
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1986
Certifications & Licensure
CA State Medical License 1999 - 2026
MA State Medical License 1988 - 2025
PA State Medical License 1998 - 2002- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Interventional Cardiology
- National Board of Physicians and Surgeons Cardiovascular Disease
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Interventional Cardiology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- Boston Magazine Castle Connolly, 2009-2012
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 3 citationsWorldwide impact of COVID-19 on hospital admissions for non-ST-elevation acute coronary syndromes (NSTACS): a systematic review with meta-analysis of 553 038 cases.Francesco Sofi, Monica Dinu, GianPaolo Reboldi, Sofia Lotti, Luca Genovese
European Heart Journal. Quality of Care & Clinical Outcomes. 2024-05-22 - 17 citationsTicagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.Marco Valgimigli, Felice Gragnano, Mattia Branca, Anna Franzone, Bruno R da Costa
JAMA Cardiology. 2024-05-01 - 4 citationsThe Single-Syringe Versus the Double-Syringe Techniques of Adenosine Administration for Supraventricular Tachycardia: A Systematic Review and Meta-Analysis.Isabele A Miyawaki, Cintia Gomes, Vittoria Caporal S Moreira, Isabela R Marques, Isabela A F de Souza
American Journal of Cardiovascular Drugs. 2023-07-01
Journal Articles
- Asymptomatic Deep Vein Thrombosis Is Associated with an Increased Risk of Death: Insights from the APEX TrialIqra Qamar, Gerald Chi, Adrian F Hernandez, C Michael Gibson, Serge Korjian, Samuel Z Goldhaber, Thrombosis and Haemostasis
- Impact of Lesion Complexity on Peri-Procedural Adverse Events and the Benefit of Potent Intravenous Platelet Adenosine Diphosphate Receptor Inhibition After Percutaneo...Gregg W Stone, Matthew J Price, Philippe Genereux, C Michael Gibson, Deepak L Bhatt, Robert A Harrington, Kenneth W Mahaffey, European Heart Journal
- Original Investigation Fatal or Irreversible Bleeding and Ischemic Events with Rivaroxaban in Acute Coronary SyndromeWilliam J Gibson, Eugene Braunwald, C Michael Gibson, ScienceDirect
- Join now to see all
Authored Content
- Original Investigation Editorial Comment Conundrum of Using Real-World Observational Data to Inform Real-World Conclusions About Safety and Efficacy∗October 2018
- Ongoing ‘Stent Wars’ May Be Resolved by PricingOctober 2018
- 4 Standout Sessions from SCAI 2018April 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
